Harvard Historical Income Statement
| HBIO Stock | USD 2.20 0.01 0.46% |
Historical analysis of Harvard Bioscience income statement accounts such as Total Revenue of 96.8 M or Gross Profit of 48.5 M can show how well Harvard Bioscience performed in making a profits. Evaluating Harvard Bioscience income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Harvard Bioscience's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Harvard Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Harvard Bioscience is a good buy for the upcoming year.
Harvard |
About Harvard Income Statement Analysis
Harvard Bioscience Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Harvard Bioscience shareholders. The income statement also shows Harvard investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Harvard Bioscience Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Harvard Bioscience generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Harvard Bioscience minus its cost of goods sold. It is profit before Harvard Bioscience operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Harvard Bioscience. It is also known as Harvard Bioscience overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Harvard Bioscience's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Interest Income is very stable compared to the past year. As of the 1st of December 2024, Reconciled Depreciation is likely to grow to about 7.8 M, while Depreciation And Amortization is likely to drop about 4.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 67.7M | 60.8M | 66.1M | 48.5M | Total Revenue | 118.9M | 113.3M | 112.3M | 96.8M |
Harvard Bioscience income statement Correlations
Click cells to compare fundamentals
Harvard Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harvard Bioscience income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.7M | 7.6M | 7.6M | 7.6M | 7.0M | 4.3M | |
| Interest Expense | 5.4M | 4.8M | 1.5M | 2.2M | 3.6M | 3.8M | |
| Total Revenue | 116.2M | 102.1M | 118.9M | 113.3M | 112.3M | 96.8M | |
| Gross Profit | 64.3M | 58.0M | 67.7M | 60.8M | 66.1M | 48.5M | |
| Other Operating Expenses | 114.3M | 101.9M | 116.8M | 120.5M | 110.4M | 93.3M | |
| Operating Income | 1.5M | (585K) | 1.4M | (7.2M) | 1.9M | 2.0M | |
| Ebit | 1.5M | (2.1M) | 3.7M | (6.6M) | 1.0M | 983.3K | |
| Research Development | 10.7M | 8.7M | 10.8M | 12.3M | 11.8M | 6.4M | |
| Ebitda | 7.2M | 5.5M | 11.3M | 944K | 8.0M | 7.8M | |
| Cost Of Revenue | 51.9M | 44.1M | 51.3M | 52.5M | 46.2M | 48.3M | |
| Total Operating Expenses | 62.5M | 57.8M | 65.6M | 68.0M | 64.5M | 44.9M | |
| Income Before Tax | (5.5M) | (7.3M) | (140K) | (9.2M) | (2.6M) | (2.7M) | |
| Total Other Income Expense Net | (7.0M) | (7.5M) | (2.2M) | (2.2M) | (4.5M) | (4.7M) | |
| Net Income | (4.7M) | (7.8M) | (288K) | (9.5M) | (3.4M) | (3.6M) | |
| Income Tax Expense | (815K) | 518K | 148K | 337K | 859K | 807.3K | |
| Selling General Administrative | 22.8M | 23.5M | 24.3M | 24.5M | 22.8M | 23.3M | |
| Selling And Marketing Expenses | 23.3M | 19.9M | 24.6M | 25.0M | 24.1M | 22.9M | |
| Net Income Applicable To Common Shares | (4.7M) | (7.8M) | (288K) | (9.5M) | (8.6M) | (8.1M) | |
| Net Income From Continuing Ops | (4.7M) | (7.8M) | (288K) | (9.5M) | (3.3M) | (3.4M) | |
| Non Operating Income Net Other | (469K) | (2.7M) | (666K) | 302K | 271.8K | 285.4K | |
| Tax Provision | (815K) | 518K | 148K | 337K | 918K | 1.1M | |
| Net Interest Income | (5.4M) | (4.8M) | (1.5M) | (2.5M) | (3.7M) | (3.9M) | |
| Reconciled Depreciation | 7.7M | 7.6M | 7.6M | 7.6M | 7.2M | 7.8M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.